Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 13 Apr 2016
Price : $35 *
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Apr 2016 Protocol amended as time frame for primary endpoints changed from upto 10 days - day 4 as reported by ClinicalTrials.gov.
- 08 Apr 2016 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2014 Status changed to completed according to ClinicalTrials.gov .